|  | Cancer | Lymphoma

Rituxan (Rituximab) for Non-Hodgkin Lymphoma: Treatment Regimens & Expectations

Rituximab (anti-CD20 monoclonal antibody) is a cornerstone of B-cell NHL treatment. Regimens are tailored by histology, stage, age, fitness, and molecular markers.

Major NHL Subtypes & Standard Frontline Approaches

  • DLBCL (Diffuse Large B-Cell): R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone) × 6 cycles ± radiation. Cure rate ~60–70%.
  • Follicular Lymphoma: Rituximab + chemo (bendamustine, CHOP, CVP) → rituximab maintenance × 2 yrs. Incurable but highly manageable.
  • Mantle Cell: Intensive chemo (R-hyperCVAD, Nordic) → autologous stem cell transplant consolidation. BTK inhibitors (ibrutinib, acalabrutinib) for relapse.
  • Marginal Zone: Rituximab ± chemo; localized → radiation.
  • Burkitt: Intensive regimens (CODOX-M/IVAC, hyperCVAD) + rituximab. High cure rate.

Key Treatment Modalities

  • Immunochemotherapy: Rituximab + chemo backbone (synergistic)
  • Targeted agents: BTK inhibitors, PI3Kδ inhibitors (idelalisib, copanlisib), BCL-2 inhibitor (venetoclax), EZH2 inhibitor (tazemetostat)
  • CAR-T cell therapy: Axicabtagene, tisagenlecleucel, lisocabtagene for relapsed/refractory DLBCL, follicular, mantle cell
  • Bispecific antibodies: Mosunetuzumab, epcoritamab, glofitamab (CD20×CD3)
  • Stem cell transplant: Auto (consolidation), allo (relapse post-auto)
  • Radiation: Consolidation for bulky/early-stage disease

Maintenance & Surveillance

Rituximab maintenance (every 2–3 months × 2 yrs) prolongs remission in follicular, mantle cell. Regular CT/PET, labs, clinical assessment.

Multidisciplinary team (hem/onc, path, rad onc, transplant, pharmacy, supportive care) optimizes outcomes.

Lymphoma - Related Articles